ToxSci Advance Access originally published online on April 15, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences 73, 209-215 (2003)
Copyright © 2003 by the Society of Toxicology
FORUM |
Workshop Overview: Use of Genomic Data in Risk Assessment
* National Center for Toxicogenomics and the National Toxicology Program, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, North Carolina 27709;
E. I. du Pont de Nemours & Co., Haskell Laboratory, P.O. Box 50, Newark, Delaware 19714;
Department of Biochemistry and Molecular Biology, Michigan State University, 223 Biochemistry Building, Wilson Road, East Lansing, Michigan 48824; and
Birth Defects Research Center, Department of Pediatrics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226
The completion of the Human Genome Project has provided the foundation to analyze the expression of all genes transcribed in a specific cell, as well as a reference against which to assess genetic variability and its impact on susceptibility. Recent advances in genomic technologies have set the stage for better understanding and predicting individual adaptive and toxicological responses after toxicant exposure. Thus, it is now possible to simultaneously assess expression levels for thousands of different genes using DNA microarrays, as well as assess posttranscriptional and posttranslational events using high throughput proteomics. Similarly, the risk of toxicant exposure-induced disease used to be estimated across populations with widely varying responses. However, new high-throughput genomic technologies have the potential to greatly improve the accuracy of risk assessment, allowing identification of sensitive subpopulations at risk and ultimately leading to personalized risk profiles based on genetic composition. Recognizing the importance these technologies will have on the practice of risk assessment and the development of regulatory guidelines, the Society of Toxicology sponsored a workshop to evaluate the current status of genomic research; the ethical, legal, and social issues associated with these approaches; and, in this context, how data derived from these technologies would impact risk assessment. This article summarizes the evaluation by experts in genomic research and risk assessment in the first workshop to provide a forum for interaction between these scientific disciplines.
Key Words: Human Genome Project; genomic research; high-throughput genomic technologies; risk assessment; regulatory guidelines.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. F. Fliri, W. T. Loging, P. F. Thadeio, and R. A. Volkmann Analysis of Drug-Induced Effect Patterns: Linking Structure and Effect of Medicines Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 236 - 242. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Currie, V. Bombail, J. D. Oliver, D. J. Moore, F. L. Lim, V. Gwilliam, I. Kimber, K. Chipman, J. G. Moggs, and G. Orphanides Gene Ontology Mapping as an Unbiased Method for Identifying Molecular Pathways and Processes Affected by Toxicant Exposure: Application to Acute Effects Caused by the Rodent Non-Genotoxic Carcinogen Diethylhexylphthalate Toxicol. Sci., August 1, 2005; 86(2): 453 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. van Leeuwen, R. W. H. Gottschalk, M. H. van Herwijnen, E. J. Moonen, J. C. S. Kleinjans, and J. H. M. van Delft Differential Gene Expression in Human Peripheral Blood Mononuclear Cells Induced by Cigarette Smoke and Its Constituents Toxicol. Sci., July 1, 2005; 86(1): 200 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Cunningham and L. Lehman-McKeeman Applying Toxicogenomics in Mechanistic and Predictive Toxicology Toxicol. Sci., February 1, 2005; 83(2): 205 - 206. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Battershill Toxicogenomics: regulatory perspective on current position Human and Experimental Toxicology, January 1, 2005; 24(1): 35 - 40. [Abstract] [PDF]
|
|